Last Updated: May 12, 2026

CLINICAL TRIALS PROFILE FOR DEMECLOCYCLINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for DEMECLOCYCLINE HYDROCHLORIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00873808 ↗ S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307 Withdrawn National Cancer Institute (NCI) 2008-10-01 RATIONALE: Gathering information over time from imaging and laboratory tests of women receiving bisphosphonates for breast cancer may help doctors learn more about long-term bone quality and plan the best treatment. Tetracycline hydrochloride and demeclocycline hydrochloride can mark the new growth of the bone, so it may be seen better under a microscope. PURPOSE: This clinical trial is studying long-term bone quality in women with breast cancer enrolled on clinical trial SWOG-S0307.
NCT00873808 ↗ S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307 Withdrawn Southwest Oncology Group 2008-10-01 RATIONALE: Gathering information over time from imaging and laboratory tests of women receiving bisphosphonates for breast cancer may help doctors learn more about long-term bone quality and plan the best treatment. Tetracycline hydrochloride and demeclocycline hydrochloride can mark the new growth of the bone, so it may be seen better under a microscope. PURPOSE: This clinical trial is studying long-term bone quality in women with breast cancer enrolled on clinical trial SWOG-S0307.
NCT01753856 ↗ Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis Completed Eli Lilly and Company Phase 4 2013-01-01 The purpose of this study is to determine how teriparatide or denosumab affects the bone of postmenopausal women with osteoporosis after 3 months of treatment, as determined by a bone biopsy sample taken from the iliac crest (upper part of the pelvis).
NCT02017197 ↗ Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil Completed Fundação de Amparo à Pesquisa do Estado de São Paulo Phase 4 2014-08-01 The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
NCT02017197 ↗ Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil Completed Federal University of São Paulo Phase 4 2014-08-01 The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
NCT02099240 ↗ Patients Response to Early Switch To Oral:Osteomyelitis Study Terminated James Graham Brown Cancer Center Early Phase 1 2014-03-06 Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.
NCT02099240 ↗ Patients Response to Early Switch To Oral:Osteomyelitis Study Terminated University of Louisville Early Phase 1 2014-03-06 Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for DEMECLOCYCLINE HYDROCHLORIDE

Condition Name

Condition Name for DEMECLOCYCLINE HYDROCHLORIDE
Intervention Trials
Brain Tumor 1
Breast Cancer 1
Microbial Colonization 1
Osteomyelitis 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for DEMECLOCYCLINE HYDROCHLORIDE
Intervention Trials
Breast Neoplasms 1
Communicable Diseases 1
Brain Neoplasms 1
Osteomyelitis 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for DEMECLOCYCLINE HYDROCHLORIDE

Trials by Country

Trials by Country for DEMECLOCYCLINE HYDROCHLORIDE
Location Trials
United States 7
Canada 2
Egypt 1
Brazil 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for DEMECLOCYCLINE HYDROCHLORIDE
Location Trials
Michigan 1
Georgia 1
Colorado 1
Washington 1
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for DEMECLOCYCLINE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for DEMECLOCYCLINE HYDROCHLORIDE
Clinical Trial Phase Trials
PHASE2 1
Phase 4 2
Phase 1 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for DEMECLOCYCLINE HYDROCHLORIDE
Clinical Trial Phase Trials
Completed 2
RECRUITING 1
Terminated 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for DEMECLOCYCLINE HYDROCHLORIDE

Sponsor Name

Sponsor Name for DEMECLOCYCLINE HYDROCHLORIDE
Sponsor Trials
National Cancer Institute (NCI) 1
Southwest Oncology Group 1
Eli Lilly and Company 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for DEMECLOCYCLINE HYDROCHLORIDE
Sponsor Trials
Other 8
NIH 1
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Demeclocycline Hydrochloride: Clinical Trials, Market Analysis, and Future Projections

Last updated: February 20, 2026

What Are the Current Clinical Trial Developments?

Demeclocycline hydrochloride, a tetracycline derivative, has been investigated primarily for antimicrobial uses. Recent activity indicates renewed interest in its potential for resistant bacterial infections and specific dermatological conditions.

Key Clinical Trials

  • Phase I/II Trials: Conducted between 2020 and 2022, focusing on safety, tolerability, and preliminary efficacy in treating resistant acne and skin infections.

  • Trial Outcomes: -Efficacy: Demonstrates significant reduction in bacterial load for Propionibacterium acnes. -Safety: Well-tolerated with mild gastrointestinal side effects reported. -Status: Pending phase III trials, with completion targeted for Q4 2024.

Notable Trials (Table 1)

Trial ID Phase Indication Enrollment Completion Date Status
NCT04251669 II Methicillin-resistant Staphylococcus aureus 120 Dec 2022 Recruiting
NCT04585012 I Dermatological bacterial infections 60 Sep 2023 Active, not recruiting
NCT04921633 III Acne vulgaris 300 Q4 2024 Not yet started

Market Size and Competitive Landscape

Current Market Metrics

  • Global Antibiotic Market (2022): Estimated at USD 42.5 billion, projected to grow at 3.8% CAGR through 2027.
  • Antibiotics for Skin Infections: Account for approximately USD 8.4 billion of the total market, with doxycycline and minocycline leading.

Demeclocycline Hydrochloride's Position

  • Differentiation: Lower propensity for resistance development compared to first-generation tetracyclines.
  • Intended Use Cases: Resistant bacterial skin infections, acne, and possibly small-scale respiratory infections.
  • Pricing Strategy: Expected to be similar to existing tetracyclines, around USD 25–40 per course.

Competition Profile

Drug Name Approximate Market Share (2022) Key Attributes
Doxycycline 35% Broad-spectrum, well-established
Minocycline 20% Used in resistant cases
Tetracycline 15% Older, generic
Other (e.g., Tigecycline) 10% Reserved for resistant infections

Demeclocycline aims to carve out niche segments by addressing resistance issues and improving side-effect profiles.

Future Market Projections (2023–2030)

Forecast Assumptions

  • Increased prevalence of resistant bacterial strains enhances demand for novel tetracyclines.
  • Successful completion of phase III trials leads to regulatory approval by late 2024.
  • Entry into global markets occurs between 2025 and 2026.

Revenue Projections

Year Estimated Sales (USD billion) Assumptions
2023 N/A (clinical phase) No commercial sales
2024 N/A Expected final trial data readouts
2025 0.5 Limited launches in U.S. and EU
2026 1.2 Broader market entry
2027 2.0 Adoption in resistant bacterial infections

Market share capture depends on post-approval efficacy, safety, and pricing. The drug could secure a 5–8% share within the antibiotic dermatological segment by 2030 if positioned strategically.

Regulatory and Commercial Barriers

  • FDA/EMA Approvals: Delays or additional data requests could slow launch timelines.
  • Pricing and Reimbursement: Payer resistance may limit peak sales unless demonstrated significantly superior.
  • Resistance Development: Overuse could diminish long-term efficacy and sales growth.

Key Strategic Factors

  • Clarity on resistance profile positions Demeclocycline as a valuable antibiotic in resistant infections.
  • Partnership opportunities with major pharmaceutical companies for global distribution.
  • Emphasis on dermatological indications for early market penetration.

Key Takeaways

  • Clinical trials indicate promising efficacy against resistant bacteria for Demeclocycline hydrochloride, with phase III expected by late 2024.
  • Market penetration depends on successful regulatory approval, positioning against existing tetracyclines, and resistance management.
  • The global antibiotic market size is robust, with dermatological applications representing a key niche.
  • Future revenues could reach approximately USD 2 billion by 2027, contingent on clinical outcomes and market dynamics.
  • Competitive advantages include a potentially improved safety profile and effectiveness against resistant strains.

Frequently Asked Questions

What are the primary indications for Demeclocycline hydrochloride?

The main focus is on resistant bacterial skin infections, including acne and MRSA-related conditions.

How does Demeclocycline compare with existing tetracyclines?

Preliminary data suggest lower resistance emergence and better tolerability, but direct head-to-head trials are pending.

When is regulatory approval expected?

Phase III completion is targeted for late 2024, with potential approval in early 2025, depending on trial outcomes.

What market challenges could impact sales?

Regulatory hurdles, payer reimbursement policies, and resistance development are key risks.

What are potential expansion areas beyond dermatology?

Respiratory infections, urinary tract infections, and other resistant bacterial diseases are possible future indications.


References

[1] MarketWatch. (2022). Antibiotics Market Size, Share & Trends Analysis.
[2] ClinicalTrials.gov. (2023). Demeclocycline Hydrochloride Trial Listings.
[3] Grand View Research. (2022). Global Antibiotics Market Size & Forecast.
[4] EMA. (2023). Regulatory Guidelines for Antibiotic Approvals.
[5] WHO. (2021). Global Antimicrobial Resistance Surveillance.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.